Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Neurochem Int ; 149: 105142, 2021 10.
Artigo em Inglês | MEDLINE | ID: mdl-34314789

RESUMO

Through the efficient clearance of extracellular glutamate, high affinity astrocytic glutamate transporters constantly shape excitatory neurotransmission in terms of duration and spreading. Even though the glutamate transporter GLT-1 (also known as EAAT2/SLC1A2) is amongst the most abundant proteins in the mammalian brain, its density and activity are tightly regulated. In order to study the influence of changes in the expression of GLT-1 on glutamate uptake capacity, we have developed a model in HEK cells where the density of the transporter can be manipulated thanks to a tetracycline-inducible promoter. Exposing the cells to doxycycline concentration-dependently increased GLT-1 expression and substrate uptake velocity. However, beyond a certain level of induction, increasing the density of transporters at the cell surface failed to increase the maximal uptake. This suggested the progressive generation of a pool of spare transporters, a hypothesis that was further validated using the selective GLT-1 blocker WAY-213613 of which potency was influenced by the density of the transporters. The curve showing inhibition of uptake by increasing concentrations of WAY-213613 was indeed progressively rightward shifted when tested in cells where the transporter density was robustly induced. As largely documented in the context of cell-surface receptors, the existence of 'spare' glutamate transporters in the nervous tissue and particularly in astrocytes could impact on the consequences of physiological or pathological regulation of these transporters.


Assuntos
Encéfalo/metabolismo , Antagonistas de Aminoácidos Excitatórios/farmacologia , Transportador 2 de Aminoácido Excitatório/antagonistas & inibidores , Transportador 2 de Aminoácido Excitatório/metabolismo , Neurônios/metabolismo , Animais , Encéfalo/efeitos dos fármacos , Células Cultivadas , Relação Dose-Resposta a Droga , Doxiciclina/farmacologia , Glutamina/metabolismo , Células HEK293 , Humanos , Neurônios/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley
2.
Exp Neurol ; 286: 1-11, 2016 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-27641322

RESUMO

Tactile hypersensitivity is one of the most debilitating symptoms of neuropathic pain syndromes. Clinical studies have suggested that its presence at early postoperative stages may predict chronic (neuropathic) pain after surgery. Currently available animal models are typically associated with consistent tactile hypersensitivity and are therefore limited to distinguish between mechanisms that underlie tactile hypersensitivity as opposed to mechanisms that protect against it. In this study we have modified the rat model of spared nerve injury, restricting the surgical lesion to a single peripheral branch of the sciatic nerve. This modification reduced the prevalence of tactile hypersensitivity from nearly 100% to approximately 50%. With this model, we here also demonstrated that the Regulator of G protein Signaling 4 (RGS4) was specifically up-regulated in the lumbar dorsal root ganglia and dorsal horn of rats developing tactile hypersensitivity. Intrathecal delivery of the RGS4 inhibitor CCG63802 was found to reverse tactile hypersensitivity for a 1h period. Moreover, tactile hypersensitivity after modified spared nerve injury was most frequently persistent for at least four weeks and associated with higher reactivity of glial cells in the lumbar dorsal horn. Based on these data we suggest that this new animal model of nerve injury represents an asset in understanding divergent neuropathic pain outcomes, so far unravelling a role of RGS4 in tactile hypersensitivity. Whether this model also holds promise in the study of the transition from acute to chronic pain will have to be seen in future investigations.


Assuntos
Hiperalgesia/etiologia , Traumatismos dos Nervos Periféricos/complicações , Proteínas RGS/metabolismo , Regulação para Cima/fisiologia , Potenciais de Ação/efeitos dos fármacos , Potenciais de Ação/fisiologia , Análise de Variância , Animais , Benzotiazóis/farmacologia , Biofísica , Proteínas de Ligação ao Cálcio/metabolismo , Modelos Animais de Doenças , Estimulação Elétrica , Feminino , Lateralidade Funcional , Gânglios Espinais/efeitos dos fármacos , Gânglios Espinais/metabolismo , Proteína Glial Fibrilar Ácida/metabolismo , Hiperalgesia/metabolismo , Hiperalgesia/patologia , Proteínas dos Microfilamentos/metabolismo , Limiar da Dor/efeitos dos fármacos , Limiar da Dor/fisiologia , Traumatismos dos Nervos Periféricos/metabolismo , Pirimidinas/farmacologia , Proteínas RGS/antagonistas & inibidores , Proteínas RGS/genética , RNA Mensageiro/metabolismo , Ratos , Ratos Sprague-Dawley , Corno Dorsal da Medula Espinal/efeitos dos fármacos , Corno Dorsal da Medula Espinal/metabolismo , Fatores de Tempo , Regulação para Cima/efeitos dos fármacos
3.
Neurosci Res ; 95: 78-82, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25697394

RESUMO

Spinal glial reactivity has been strongly implicated in pain that follows peripheral nerve injury. Among the many therapeutic agents that have been tested for anti-allodynia through immune modulation is the atypical methylxanthine propentofylline. While propentofylline shows a potent anti-allodynia effect after nerve transection injury, we here demonstrate that, when propentofylline is used intrathecally at the effective immune-modulatory dose, allodynia after rat nerve crush injury is completely preserved. Microglial/macrophage Iba-1 and astrocytic GFAP expression, increased in the dorsal horn of nerve crushed animals, was, however, effectively attenuated by propentofylline. Effective modulation of spinal glial reactivity is, thus, no assurance for anti-allodynia.


Assuntos
Hiperalgesia/metabolismo , Hiperalgesia/psicologia , Neuroglia/efeitos dos fármacos , Neuroglia/metabolismo , Corno Dorsal da Medula Espinal/metabolismo , Xantinas/administração & dosagem , Animais , Proteínas de Ligação ao Cálcio/metabolismo , Feminino , Proteína Glial Fibrilar Ácida/metabolismo , Hiperalgesia/tratamento farmacológico , Injeções Espinhais , Proteínas dos Microfilamentos/metabolismo , Compressão Nervosa , Neuralgia/tratamento farmacológico , Neuralgia/metabolismo , Limiar da Dor/efeitos dos fármacos , Ratos , Ratos Sprague-Dawley , Recuperação de Função Fisiológica/efeitos dos fármacos , Nervo Isquiático/lesões , Corno Dorsal da Medula Espinal/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...